AusBiotech says the Government's R&D tax bill still penalises the clinical trial and manufacturing companies Australia most wants to keep. The industry body is now pushing for changes in the Senate.
AusBiotech has moved its campaign on the Research and Development Tax Incentive to the Senate. The legislation tabled in the House of Representatives on Tuesday leaves the sector's main concern unresolved.
The Treasury Laws Amendment (Tax Reform No. 4) Bill 2026 puts the R&D Tax Incentive changes from the May Budget into law. It also creates the Innovative Business CGT Concession for start-up founders, employees and investors.
AusBiotech chief executive Rebekah Cassidy said the government had made "genuine improvements in both pieces of legislation". She welcomed the new consultation on core and supporting R&D as "a positive step".
Her concern is the 15-year age limit on the refundable offset, which pays cash to companies that are not yet profitable. Cassidy said it would hit companies running clinical trials in complex disease areas and those that have begun building local advanced manufacturing.
"These are the very companies that Australia has long wanted to grow. A 15-year age limit pulls against this long-held ambition," she said.
The Budget measure limited refundability to firms in their first ten years. The bill extends that to 15 years for companies whose R&D mainly aims to generate new knowledge about therapeutic goods. After that, firms with turnover under $50 million keep the higher offset rate, but only as a non-refundable credit.
The bill also lifts the turnover threshold for the refundable offset from $20 million to $50 million and raises core R&D offset rates. It removes supporting R&D activities and increases the minimum annual claim from $20,000 to $50,000, all from 1 July 2028.
Treasurer Jim Chalmers told Parliament the reforms "are expected to lift investment in R&D by young firms by $400 million per year."
On supporting R&D, the bill gives a Treasury Minister power to prescribe activities as integral to core R&D, after consulting the Industry Minister. The explanatory memorandum makes clear this falls short of restoring support for these activities. Further consultation, including on clinical manufacturing, is promised for early 2027.
The Government had already shifted on capital gains. The new concession keeps a 50 per cent discount on qualifying start-up equity once the general discount is replaced in July 2027. It now covers companies up to 15 years old rather than ten, with a three-year holding period and no lifetime cap. AusBiotech had sought a longer window or none at all, and recognition that biotechs list earlier than other companies. Listed companies remain excluded.
Since May, AusBiotech has lodged submissions, appeared before a Senate inquiry and met ministers across portfolios. It has also led three joint letters from up to 18 health, science and research organisations. Cassidy and Director of Government and Policy Karyn McIntosh briefed Senators on Tuesday and will return to Parliament House.
"It would not be a surprise to know that Government has the numbers to pass this legislation unchanged in the Lower House, which means any further changes will require discussion in the Senate," Cassidy said.